SAVE MONEY ON TRAVEL DEALS

Researchers at the University of Pennsylvania School of Medicine and colleagues at Sangamo BioSciences Inc. of Richmond, Calif., said their goal is to use modified T cells from an HIV-infected person for that person's own treatment. They showed that, by using the zinc fingers, they could reduce the viral load of immune-deficient mice transplanted with engineered T cells.

The researchers, led by Dr. Elena Perez, an assistant professor of pediatrics, and Dr. Carl June, a professor of pathology and laboratory medicine at Penn, are planning a clinical trial in humans in which T cells from HIV patients would have their CCR5 gene -- necessary for the AIDS virus to enter immune system cells -- deliberately knocked out.

The modified T cells could then be infused back into the patients to re-establish their immune system and decrease their viral load.

The research is reported online in the journal Nature Biotechnology.

 BREAKING STORIES

Non-smokers live longer and better

Study: Alcohol reduces brain volume

Prostate drug not linked to hip fracture

Boeing machinists strike talks fall apart

Blood pressure drug helps reduce plaque

Nursing mother can pass on codeine to baby

Pre-sale orders for Android phone take off

Eating green helps planet and waistlines

Wash. assisted suicide measure debated

IAEA says inspectors back in N.Korea

Apple finds mobile phone pack on its tail

Pectin appears to cut cancer risk

Cisco's has new view of emerging markets

New, powerful pain control method studied

Blood replication proteins are identified

Statins may help avoid some miscarriages

New delivery system hikes vaccine response

3-D mobile device displays being developed

Beavers' dams found good for songbirds

Massive cyclones found at Saturn's poles